5 articles
India's Cipla missed Q2 profit estimates as net earnings fell to 8.78 billion rupees due to weak US sales of generic Revlimid. While North American revenue declined 19%, Indian operations grew 12%, pa
Indian equities are poised to rise amid fading U.S. rate hike fears, with Brent crude stabilizing near $96. Key industry updates include Cipla securing a biosimilar Keytruda license and potential Fosu
Indian equities gained as oil prices fell on Strait of Hormuz de-escalation hopes. Sector updates included Cipla facing FDA observations, Dabur winning a court stay on food claims, and Honasa cancelli
Cipla's Q1 profit fell 39.2% to 7.89 billion rupees, missing estimates due to muted generic cancer drug sales and supply disruptions affecting lanreotide in its U.S. business.
Alembic Pharmaceuticals posted a 29.2% rise in fourth-quarter profit to 2.03 billion rupees, driven by strong U.S. generics demand. Overall revenue increased 4.4%, contrasting with weaker results from
ChemBrief